Business Wire

MA-INRUPT

23.7.2024 14:01:30 CEST | Business Wire | Press release

Share
Inrupt launches multi-purpose Data Wallet designed for the next phase of the web

Today, Inrupt, the leading provider of enterprise-grade software for the web, announced the launch of its Data Wallet. Enterprises and governments use the technology to give their customers and citizens digital wallets for their data, creating a foundation for innovative, intuitive and impactful digital experiences.

Over 60% of the world’s population is expected to use digital wallets regularly by 2026, and over half of consumers report interest in using them for a broader range of purposes. But the existing market has focused largely on financial transactions and is dominated by a handful of Big Tech vendors.

Inrupt’s Data Wallet technology represents the next evolution of standard, interoperable digital wallets. Unlike alternatives, Inrupt’s solution accepts a wide variety of data and makes it easy for individuals to consent to access their data. The Data Wallet opens new opportunities for organizations as the web shifts toward a user-centric approach to how personal data is managed, shared, and used.

“Browsers shaped the Web 1.0 era, and Web 2.0 was all about apps. But Web 3.0 is all about empowered individuals and personal data. The Data Wallet becomes a fundamental tool for users,” said Sir Tim Berners-Lee, inventor of the World Wide Web and CTO and co-founder of Inrupt. “By making this key piece of technology available, Inrupt is ensuring that the opportunities and benefits of secure personal Data Wallets are open for everyone.”

The explosion of new use cases for digital wallets, and the types of data they store, represents a major shift in consumer behavior. For organizations, it’s a chance to improve and grow relationships with customers and citizens. In order to capitalize on the opportunity that digital wallets represent, organizations can rely on Inrupt’s standards-based approach to quickly build, integrate, and test new wallet offerings — or enhance their current wallet applications — all while giving users confidence that they have transparency and control of their most important personal data.

"Digital wallets are fast becoming the most compelling way to serve your customers and citizens. Organizations need to assess their wallet strategy,” said John Bruce, CEO and co-founder of Inrupt. “We built our Data Wallet to be easy to use — both for organizations and their users. It’s a direct channel of communication for valuable, relevant data."

Until now, digital wallets have been siloed “point solutions,” requiring different wallets for different purposes. But global initiatives like the EU’s Digital Identity Wallet are already showing organizations the benefits of standardization and interoperability. With a multi-purpose Data Wallet, organizations can access and verify government-issued credentials like passports, educational certificates and entitlement benefits, even across state and national borders.

Inrupt’s Data Wallet solution is built on the company’s Enterprise Solid Server (ESS), which is powering mission-critical deployments of the Solid protocol, the open web standard, around the world. Because of this foundation, it’s easy to reuse the personal data stored in the Data Wallet in other apps, services and AI systems. Consent for access is always coupled with each piece of data, so users can trust their data is used the way they want, and organizations can be confident they’re in compliance with any relevant data regulations.

“Digital wallets aren’t just for payments anymore. With the Data Wallet adding identity and consent capabilities, they are quickly becoming the gateway to our digital lives and will soon be the main interface used for data sharing, management and collaboration,” said Osmar Olivo, VP of Product at Inrupt. “By moving towards standardization with an underlying infrastructure like Solid, this wealth of information can be used flexibly, securely, and as intended across any sector in order to deliver better services, products, or experiences.”

“It’s clear that digital wallets are the new basecamp for a huge variety of digital activities. What’s not yet determined is whether this change will reinforce the power of the few, or open new advantages for the many,” said John Bruce. “Inrupt will always build technology intended to benefit the many, and our Data Wallet is the most important example yet.”

Click here to learn more about Inrupt’s Data Wallet features and capabilities or request a demo.

About Inrupt

Inrupt is a leading provider of enterprise-grade software for the web. Enterprises and governments rely on our technology to build new, innovative products and services — all based on a platform of interoperable data and consent from customers and citizens.

Co-founded by World Wide Web inventor Sir Tim Berners-Lee, Inrupt scales and secures the Solid protocol, the open web standard. The company’s Enterprise Solid Server (ESS) stores and protects personal data for enterprises and governments. On this foundation they can quickly build user Data Wallets and applications that take advantage of this new source of authentic data directly from customers and citizens.

Inrupt’s global presence spans the US, UK, Europe and APAC. The company works with organizations across various sectors, including Financial Services, Retail, Government, Healthcare, and Media/Telco. Founded in 2017, Inrupt’s mission is to ensure a better, safer future of data, AI, and the web.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240723678725/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye